238 related articles for article (PubMed ID: 21364123)
21. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
24. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
25. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
26. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Mellinghoff IK; Vivanco I; Kwon A; Tran C; Wongvipat J; Sawyers CL
Cancer Cell; 2004 Nov; 6(5):517-27. PubMed ID: 15542435
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations associated with LNCaP cell progression to androgen independence.
Shi XB; Ma AH; Tepper CG; Xia L; Gregg JP; Gandour-Edwards R; Mack PC; Kung HJ; deVere White RW
Prostate; 2004 Aug; 60(3):257-71. PubMed ID: 15176055
[TBL] [Abstract][Full Text] [Related]
28. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
29. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
31. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
[TBL] [Abstract][Full Text] [Related]
32. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
33. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
35. Suppression of breast cancer cell growth by Her2-reduced AR serine 81 phosphorylation.
Huang PH; Wang HY; Huang CC; Lee YT; Yue CH; Chen MC; Lin H
Chin J Physiol; 2016 Aug; 59(4):232-9. PubMed ID: 27426262
[TBL] [Abstract][Full Text] [Related]
36. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
[TBL] [Abstract][Full Text] [Related]
37. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
38. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.
Wright ME; Tsai MJ; Aebersold R
Mol Endocrinol; 2003 Sep; 17(9):1726-37. PubMed ID: 12775765
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma.
Wang HY; Lin WY; Chen MC; Lin T; Chao CH; Hsu FN; Lin E; Huang CY; Luo TY; Lin H
Int J Radiat Biol; 2013 May; 89(5):346-55. PubMed ID: 23294030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
